In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 7, 2007, Pages 2587-2590

  Almyroudis, Nikolaos G ^a   Sutton, Deanna A ^b,e   Fothergill, Annette W ^b   Rinaldi, Michael G ^b,c   Kusne, Shimon ^d  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Fungus Testing Laboratory   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^d MAYO CLINIC   (United States)

^e Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; POSACONAZOLE; VORICONAZOLE;

ABSIDIA; ANTIFUNGAL ACTIVITY; ARTICLE; CUNNINGHAMELLA BERTHOLLETIAE; FUNGUS ISOLATION; IN VITRO STUDY; MUCOR; NONHUMAN; PRIORITY JOURNAL; RHIZOMUCOR; RHIZOPUS; ZYGOMYCETES;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; FLUCONAZOLE; FLUCYTOSINE; HUMANS; ITRACONAZOLE; KETOCONAZOLE; MICROBIAL SENSITIVITY TESTS; MUCORMYCOSIS; PEPTIDES, CYCLIC; PYRIMIDINES; TRIAZOLES;

EID: 34447265453     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00452-07     Document Type: Article

References (30)

1. Almyroudis, N. G., D. A. Sutton, P. Linden, M. G. Rinaldi, J. Fung, and S. Kusne. 2006. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am. J. Transplant. 6:2365-2374.
2. Arikan, S., M. Lozano-Chiu, V. Paetznick, and J. H. Rex. 2001. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob. Agents Chemother. 45:327-330.
3. Bekersky, I., R. M. Fielding, D. E. Dressier, J. W. Lee, D. N. Buell, and T. J. Walsh. 2002. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob. Agents Chemother. 46:828-833.
4. Cuenca-Estrella, M., A. Gomez-Lopez, E. Mellado, M. J. Buitrago, A. Monzon, and J. L. Rodriguez-Tudela. 2006. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob. Agents Chemother. 50:917-921.
5. Dannaoui, E., J. Meletiadis, J. W. Mouton, J. F. G. M. Meis, P. E. Verweij, and the Eurofong Network. 2003. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J. Antimicrob. Chemother. 51:45-52.
6. Dannaoui, E., J. W. Mouton, J. F. G. M. Meis, P. E. Verweij, and Eurorang Network. 2002. Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis. Antimicrob. Agents Chemother. 46:1953-1959.
7. Dannaoui, E., J. F. Meis, D. Loebenberg, and P. E. Verweij. 2003. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob. Agents Chemother. 47:3647-3650.
8. Diekema, D. J., S. A. Messer, R. J. Hollis. R. N. Jones, and M. A. Pfaller. 2003. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J. Clin. Microbiol. 41:3623-3626.
9. Dromer, F., and M. R. McGinnis. 2003. Zygomycosis, p. 297-308. In E. J. Anaissie, M. R. McGinnis, and M. A. Pfaller (ed.), Clinical mycology, Churchill Livingstone, Philadelphia, PA.
10. Eisen, D. P., and J. Robson. 2004. Complete resolution of pulmonary Rhizopus oryzae infection with itraconazole treatment: more evidence of the utility of azoles for zygomycosis. Antimicrob. Agents Chemother. 47:159-162.
11. Espinel-Ingroff, A. 2006. Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B. J. Clin. Microbiol. 44:3616-3622.
12. Gonzalez, C. E., M. G. Rinaldi, and A. M. Sugar. 2002. Zygomycosis, p. 895-914. In R. C. Moellering, Jr., T. J. Walsh, and J. H. Rex (ed.), Infectious disease clinics of North America, W. B. Saunders Company, Philadelphia, PA.
13. Greenberg, R. N., K. Mullane, J.-A. H. van Burik, I. Raad, M. J. Abzug, G. Anstead, R. Herbrecht, A. Longston, K. A. Marr, G. Schiller, M. Schuster, J. R. Wingard, C. E. Gonzalez, S. G. Revankar, G. Corcoran, R. J. Kryscio, and R. Hare. 2006. Posaconazole as salvage therapy for zygomycosis. Antimicrob. Agents Chemother. 50:126-133.
14. Kontoyiannis, D. P., V. C. Wessel, G. P. Bodey, and K. V. I. Rolston. 2000. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin. Infect. Dis. 30:851-856.
15. Kontoyiannis, D. P., M. S. Lionakis, R. E. Lewis, G. Chamilos, M. Healy, C. Perego, A. Safdar, H. Kantarjian, R. Champlin, T. J. Walsh, and I. I. Raad. 2005. Zygomycosis in a tertiary-care center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J. Infect. Dis. 191:1350-1360.
16. Kurtz, M. B., I. B. Heath, J. Marrinan, S. Dreikorn, J. Onishi, and C. Douglas. 1994. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob. Agents Chemother. 38:1480-1489.
17. NCCLS/CLSI. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. Document M38-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
18. Otcenasek, M., and V. Buchta. 1994. In vitro susceptibility to 9 antifungal agents of 14 strains of zygomycetes isolated from clinical specimens. Mycopathologia 128:135-137.
19. Pfaller, M. A., F. Marco, S. A. Messer, and R. N. Jones. 1998. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792) against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbiol. Infect. Dis. 30:251-255.
20. Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, and the Sentry Participants Group. 2002. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY antimicrobial surveillance program, 2000. Antimicrob. Agents Chemother. 46:1032-1037.
21. Ribes, J. A., C. L. Vanovcr-Sams, and D. J. Baker. 2000. Zygomycosis in human disease. Clin. Microbiol. Rev. 13:236-301.
22. Roden, M. M., T. E. Zaoutis, W. L. Buchanan, T. A. Knudsen, T. A. Sarkisova, R. L. Schaufele, M. Sein, T. Sein, C. C. Chiou, J. H. Chu, D. P. Kontoyiannis, and T. J. Walsh. 2005. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 41:634-653.
23. Sabatelli, F., R. Patel, P. A. Mann, C. A. Mendrick, C. C. Norris, R. Hare, D. Loebenberg, T. A. Black, and P. M. McNichoIas. 2006. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 50:2009-2015.
24. Singh, J., D. Rimek, and R. Kappe. 2005. In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method. Mycoses 48:246-250.
25. Spellberg, B., Y. Fu, J. E. Edwards, Jr., and A. S. Ibrahim. 2005. Combined therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob. Agents Chemother. 49:830-832.
26. Sugar, A. M. 1992. Mucormycosis. Clin. Infect. Dis. 14(Suppl. 1):S126-S129.
27. Sugar, A. M. 2005. Agents of mucormycosis and related species, p. 2973-2984. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 6th ed. Churchill Livingstone, Philadelphia, Pa.
28. Sun, Q. N., A. W. Fothergill, D. I. McCarthy, M. G. Rinaldi, and J. R. Graybill. 2002. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob. Agents Chemother. 46:1581-1582.
29. Sun, N. Q., L. K. Najvar, R. Bocanegra, D. Loebenberg, and J. R. Graybill. 2002. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob. Agents Chemother. 46:2310-2312.
30. Van Burik, J.-A. H., R. S. Hare, H. F. Solomon, M. L. Corrado, and D. P. Kontoyiannis. 2006. Posaconazole is effective salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin. Infect. Dis. 42:e61-e65.